Information Provided By:
Fly News Breaks for March 29, 2017
EXAS
Mar 29, 2017 | 09:18 EDT
BofA/Merrill analyst Anne Edelstein initiated Exact Sciences with a Buy and a $29 price target telling investors Cologuard growth will beat consensus expectations and the company can achieve profitability prior to any emerging competitive threats from the liquid biopsy space.
News For EXAS From the Last 2 Days
There are no results for your query EXAS